A diverse and decentralized pharmaceutical company, Valeant focuses on key stakeholders while at the same time delivering consistently high performance.
The company is guided by values that provide an overall direction as well as the tools necessary to meet any challenge.
"We have consistently leveraged our collective hard work and effort, along with our unwavering competitive spirit," says a company spokeswoman. "These values help us to set goals that are based both on our organization's potential and our hopes for what it will become."
Following the acquisitions of Medicis, which offers branded specialty products in the dermatology and aesthetics spaces, and Obagi Medical Systems, a leader in topical aesthetics and therapeutic skin health systems, Valeant has been recognized as the largest dermatology company in the United States. In August, Valeant further expanded its portfolio by completing the acquisition of Bausch + Lomb, the global eye health company.
Medicis' portfolio includes such leading prescription brands as Solodyn, Restylane, Perlane, Ziana, Dysport and Zyclara.
The pro forma net revenue for the combined company's dermatology and aesthetics businesses for 2012 is estimated to exceed $1.7 billion within the United States.
Obagi's product portfolio includes such leading dermatology brands including Obagi Nu-Derm, Condition & Enhance, Obagi-C Rx, ELAS-TIDerm and CLENZIDerm. Obagi had total revenue of approximately $120 million in 2012.
Bausch + Lomb operates in three segments: pharmaceutical, including prescription brands, generics and over-the-counter; vision care, with such lines as contact lenses and solutions; and surgical, in such categories as intraocular lenses and surgical equipment.
Bausch + Lomb has a broad portfolio of eye health products, including such well-known prescription and O-T-C brands as Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, rent] and Boston; and surgical brands enVista, Storz, Stellaris and Victus.
"We are excited to announce the acquisition of Bausch + Lomb, which significantly strengthens our capabilities in ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments," says Valeant chairman and chief executive officer J. Michael Pearson. "Bausch + Lomb's world-renowned brand, comprehensive portfolio of leading eye care products, and promising late-stage pipeline are an ideal strategic fit for our current ophthalmology business."
Valeant's consumer products business has also been active, acquiring such brands as AcneFree, Ambi, Purpose and Ocean Saline Nasal, expanding the company's consumer product portfolio while meeting diverse consumer needs.
AcneFree represents the leading acne skin care system in stores, and Ambi has been designed to meet the skin care needs of women of color. Purpose is one of the first skin care brands developed for sensitive skin. And Ocean Saline Nasal offers non-medicated relief for dry and irritated nasal passages from allergies, colds and other conditions. Earlier in 2013, CeraVe Skincare introduced the Renewing SA Cream and the Therapeutic Hand Cream.
Valeant has also launched a full line of broad-spectrum sunscreens for the sun care season.
Valeant Pharmaceuticals North America LLC
700 Route 202/206 North, Bridgewater, N.J. 08807
Phone: (866) 246-8245